Subclinical Cardiovascular Disease in Psoriatic Disease

计划入组 63 人 · 首次发布于 2017 年 7 月 24 日

SystemIc iNflammation and Microvascular diSease PreventIon in psoRiatic diseasE

首次发布于 2020 年 6 月 4 日

Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease

计划入组 128 人 · 首次发布于 2025 年 12 月 12 日

liver disease program

Risankizumab(Skyrizi 150 Mg Dose Pack, Skyrizi)

siRNA therapeutics for ocular disease/dermatological disease (Phio Pharmaceuticals)

Rare Disease Research, LLC

CASTLEMAN DISEASE COLLABORATIVE NETWORK

United States

CURE RARE DISEASE, INC.

United States

Biologic Therapies Show Favorable Cancer Safety Profile in Psoriatic Disease Patients

Lilly's Taltz Plus Zepbound Shows Durable One-Year Benefits in Psoriatic Disease and Obesity

POSITIVE Trial Shows Tildrakizumab Delivers Comprehensive Quality of Life Benefits in Psoriatic Disease